A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (NCT07011745)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
Who can join: Review the eligibility criteria below.
Location: Chandler Clinical Trials, LLC — Chandler, Arizona
Age range: 55 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (144 Sites)
Showing the first 25 of 144 sites.
- Chandler Clinical Trials, LLC — Chandler, Arizona
- Local Institution - 2631 — Chandler, Arizona
- Local Institution - 2646 — Chandler, Arizona
- National Institute of Clinical Research — Garden Grove, California
- Local Institution - 2607 — Long Beach, California
- Accellacare — Long Beach, California
- Local Institution - 2627 — Napa, California
- Local Institution - 2649 — Orange, California
- Local Institution - 2613 — Pasadena, California
- Local Institution - 2614 — San Diego, California
- Local Institution - 2620 — West Hills, California
- Local Institution - 2601 — Basalt, Colorado
- Local Institution - 2632 — Norwalk, Connecticut
- Local Institution - 2648 — Aventura, Florida
- Envision Trials LLC — Bonita Springs, Florida
- Key Clinical Research — Bradenton, Florida
- Local Institution - 2636 — Doral, Florida
- Local Institution - 2606 — Homestead, Florida
- Miami Jewish health — Miami, Florida
- Local Institution - 2637 — Miami, Florida
- Local Institution - 2634 — Orlando, Florida
- IPTB Clinical Research — Tampa, Florida
- Agile Clinical Research Trials, LLC — Atlanta, Georgia
- Vitalix Clinical — Worcester, Massachusetts
- Local Institution - 2618 — Ann Arbor, Michigan
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer's Disease
- Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia — Calgary, Alberta
- A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology — Clermont, Florida
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Phoenix, Arizona
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease — Birmingham, Alabama
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Birmingham, Alabama
- A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Chandler, Arizona
Explore by condition: All Alzheimer's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.